J&J’s bladder hope gets its first approval
Inlexzo gets the nod in BCG-unresponsive non-muscle invasive bladder cancer, but the group has bigger plans.
World Lung 2025 – cell therapy makes a cautious start against DLL3
So far the data, with a Car-T Legend licensed to Novartis, lag antibody approaches.
AbbVie makes a bigger bet on SEZ6
But first it will need to identify the optimal dose in first-line small-cell lung cancer.
AbbVie broadens its telisotuzumab conjugate push
A new phase 2/3 will enrol a broad second-line EGFR-mutant NSCLC population.
World Lung 2025 – pumitamig confirms its small-cell promise
Global data are in the same ballpark as Chinese results presented earlier this year.
BioNTech's take on iza-bren enters the clinic
The latest projects newly into human trials include BNT3212.
World Lung 2025 – crossing curves in lung cancer
Tolerability could decide first-line therapy in EGFRm disease.
Real transparency on FDA rejections
A new batch of CRLs includes fresh revelations about patritumab deruxtecan.
